Patents by Inventor Lawrence J. Thomas

Lawrence J. Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
    Publication number: 20220227877
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 22, 2021
    Publication date: July 21, 2022
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Antibodies that bind human CD27 and uses thereof
    Patent number: 11180566
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 23, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
  • AGONISTIC ANTIBODIES THAT BIND CD40
    Publication number: 20210147538
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 20, 2021
    Applicants: Celldex Therapeutics, Inc., Celldex Therapeutics, Inc.
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
    Patent number: 10941201
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: March 9, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Nucleic acids encoding agonistic antibodies that bind CD40
    Patent number: 10865244
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: December 15, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20200377606
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 18, 2017
    Publication date: December 3, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20200369768
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Agonistic antibodies that bind CD40
    Patent number: 10633444
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 28, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20190322743
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 24, 2019
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20180066053
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 18, 2017
    Publication date: March 8, 2018
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer Widger
  • CD27 AGONISTS
    Publication number: 20180044429
    Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 15, 2018
    Inventors: Tibor KELER, Joel GOLDSTEIN, Lizhen HE, Henry C. MARSH, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Laura A. VITALE, Jenifer WIDGER
  • ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
    Publication number: 20150337047
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: July 2, 2015
    Publication date: November 26, 2015
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Antibodies that bind human CD27 and uses thereof
    Patent number: 9169325
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: October 27, 2015
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
  • V. Cholera hypereexpressing recombinant cholera toxin B subunit showing dual immunogenicity
    Publication number: 20130122039
    Abstract: Immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing Escherichia coli (ETEC) and Vibrio cholerae based on the hyperexpression of recombinant cholera toxin B antigen by attenuated, live bacterial vectors derived from Vibrio cholerae are disclosed. The compositions exhibit dual immunogenicity and retain the ability to colonize gastrointestinal mucosa-associated lymphoid tissues.
    Type: Application
    Filed: October 16, 2012
    Publication date: May 16, 2013
    Inventors: Kevin P. Killeen, Kenneth L. Roland, Lawrence J. Thomas
  • hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity
    Patent number: 8287855
    Abstract: Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing Escherichia coli (ETEC) and Vibrio cholerae based on the delivery of recombinant cholera toxin B antigen by attenuated, live bacterial vectors derived from Vibrio cholerae are disclosed. The compositions exhibit dual immunogenicity and retain the ability to colonize gastrointestinal mucosa-associated lymphoid tissues.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: October 16, 2012
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Kevin P. Killeen, Kenneth L. Roland, Lawrence J. Thomas
  • ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
    Publication number: 20120213771
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 23, 2012
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF
    Publication number: 20110274685
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 10, 2011
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • V. CHOLERAE HYPEREXPRESSING RECOMBINANT CHOLERA TOXIN B SUBUNIT SHOWING DUAL IMMUNOGENICITY
    Publication number: 20100129396
    Abstract: Oral immunogenic compositions imparting dual protection against enterotoxigenic labile toxin (LT)-expressing Escherichia coli (ETEC) and Vibrio cholerae based on the delivery of recombinant cholera toxin B antigen by attenuated, live bacterial vectors derived from Vibrio cholerae are disclosed. The compositions exhibit dual immunogenicity and retain the ability to colonize gastrointestinal mucosa-associated lymphoid tissues.
    Type: Application
    Filed: April 24, 2008
    Publication date: May 27, 2010
    Inventors: Kevin P Killeen, Kenneth L. Roland, Lawrence J. Thomas
  • Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
    Publication number: 20090142362
    Abstract: Improved vaccine compositions and methods of use thereof are described that elicit production of antibodies in an individual to the individual's own endogenous cholesteryl ester transfer protein (CETP).
    Type: Application
    Filed: November 6, 2007
    Publication date: June 4, 2009
    Applicants: Avant Immunotherapeutics, Inc., Coley Pharmaceutical Group, Inc.
    Inventors: Arthur M. Krieg, Lawrence J. Thomas, Charles W. Rittershaus
  • Modulation of cholesteryl ester transfer protein (CETP) activity
    Patent number: 7078036
    Abstract: This invention relates to peptides comprising a helper T cell epitope portion and a B cell epitope portion for eliciting an immune response against endogenous cholesteryl ester transfer protein (CETP) activity, to prevent or treat cardiovascular disease, such as atherosclerosis.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: July 18, 2006
    Assignee: Avant Immunotherapeutics, Inc.
    Inventors: Charles W. Rittershaus, Lawrence J. Thomas